title: Antiepileptic drug trials: Less placebo exposure for safer studies?
authors: From the Department de Neurologie I (M.B.), Hôpital de la Salpêtrière, APHP; Université Pierre et Marie Curie (UPMC, Paris VI) (M.B.); IHU-A (M.B.), ICM Institut du Cerveau et de la Moelle, Clinique Neurologique P Castaigne, Hôpital de la Pitie-Salpêtrière, Paris, France; and the Department of Neurology (G.D.C.), Mayo Clinic, Rochester, MN. michel.baulac@wanadoo.fr.
authors: Michel
authors: M
authors: Baulac
authors: From the Department de Neurologie I (M.B.), Hôpital de la Salpêtrière, APHP; Université Pierre et Marie Curie (UPMC, Paris VI) (M.B.); IHU-A (M.B.), ICM Institut du Cerveau et de la Moelle, Clinique Neurologique P Castaigne, Hôpital de la Pitie-Salpêtrière, Paris, France; and the Department of Neurology (G.D.C.), Mayo Clinic, Rochester, MN.
authors: Gregory D
authors: GD
authors: Cascino
mesh_terms: D000927:Anticonvulsants / Q000008:administration & dosage*; D023381:Endpoint Determination; D004828:Epilepsies, Partial / Q000188:drug therapy*; D006801:Humans; D011728:Pyridones / Q000008:administration & dosage*; D012640:Seizures / Q000188:drug therapy*
chemical_list: D000927:Anticonvulsants; D011728:Pyridones